Co-Diagnostics Inc
CODX0.235USD
-0.006-2.41%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
11.31MMarket Cap
LossP/E TTM
More Details of Co-Diagnostics Inc Company
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Co-Diagnostics Inc Info
Ticker SymbolCODX
Company nameCo-Diagnostics Inc
IPO dateJul 12, 2017
CEOEgan (Dwight H)
Number of employees132
Security typeOrdinary Share
Fiscal year-endJul 12
Address2401 S. Foothill Dr. Suite D
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84109
Phone18014381036
Websitehttps://codiagnostics.com/
Ticker SymbolCODX
IPO dateJul 12, 2017
CEOEgan (Dwight H)
Company Executives of Co-Diagnostics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard Abbott
Mr. Richard Abbott
President
President
618.65K
+2.30%
Mr. Richard S. Serbin
Mr. Richard S. Serbin
Independent Director
Independent Director
329.17K
+21.17%
Mr. James B. Nelson
Mr. James B. Nelson
Independent Director
Independent Director
326.67K
+21.36%
Mr. Brian L. Brown, CPA
Mr. Brian L. Brown, CPA
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Edward L. (Ted) Murphy
Mr. Edward L. (Ted) Murphy
Independent Director
Independent Director
--
--
Dr. Eugene Durenard, Ph.D.
Dr. Eugene Durenard, Ph.D.
Independent Director
Independent Director
--
--
Mr. Dwight H. Egan
Mr. Dwight H. Egan
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Richard Abbott
Mr. Richard Abbott
President
President
618.65K
+2.30%
Mr. Richard S. Serbin
Mr. Richard S. Serbin
Independent Director
Independent Director
329.17K
+21.17%
Mr. James B. Nelson
Mr. James B. Nelson
Independent Director
Independent Director
326.67K
+21.36%
Mr. Brian L. Brown, CPA
Mr. Brian L. Brown, CPA
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Edward L. (Ted) Murphy
Mr. Edward L. (Ted) Murphy
Independent Director
Independent Director
--
--
Dr. Eugene Durenard, Ph.D.
Dr. Eugene Durenard, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
162.91K
0.00%
Rest of the world
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ayrton Capital LLC
6.14%
Orca Capital GmbH
3.10%
The Vanguard Group, Inc.
2.80%
Private Advisory Group LLC
1.94%
Renaissance Technologies LLC
1.42%
Other
84.60%
Shareholders
Shareholders
Proportion
Ayrton Capital LLC
6.14%
Orca Capital GmbH
3.10%
The Vanguard Group, Inc.
2.80%
Private Advisory Group LLC
1.94%
Renaissance Technologies LLC
1.42%
Other
84.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.44%
Hedge Fund
7.58%
Individual Investor
5.87%
Investment Advisor/Hedge Fund
1.00%
Research Firm
0.44%
Bank and Trust
0.05%
Other
75.62%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
80
11.14M
13.43%
-308.03K
2025Q3
83
11.45M
12.86%
+6.26M
2025Q2
88
5.18M
18.12%
-695.54K
2025Q1
96
5.88M
20.77%
-1.09M
2024Q4
104
5.75M
18.48%
+1.31M
2024Q3
108
4.45M
20.26%
-229.17K
2024Q2
125
4.65M
21.94%
+232.83K
2024Q1
134
4.41M
23.86%
-3.05M
2023Q4
144
4.75M
24.82%
-54.54K
2023Q3
160
4.81M
26.97%
+93.65K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orca Capital GmbH
2.19M
4.56%
+2.19M
--
Sep 18, 2025
The Vanguard Group, Inc.
1.73M
3.6%
-44.94K
-2.53%
Jun 30, 2025
Private Advisory Group LLC
1.18M
2.45%
--
--
Jun 30, 2025
Renaissance Technologies LLC
561.02K
1.17%
+10.70K
+1.94%
Jun 30, 2025
Egan (Dwight H.)
748.18K
1.55%
+111.64K
+17.54%
May 23, 2025
Abbott (Richard David)
631.47K
1.31%
+12.82K
+2.07%
May 23, 2025
Brown (Brian Lee)
599.30K
1.24%
+86.00K
+16.76%
May 23, 2025
BlackRock Institutional Trust Company, N.A.
427.44K
0.89%
-69.29K
-13.95%
Jun 30, 2025
Serbin (Richard S)
262.50K
0.55%
+48.33K
+22.57%
May 23, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Co-Diagnostics Inc?
The top five shareholders of Co-Diagnostics Inc are:
Orca Capital GmbH holds 2.19M shares, accounting for 4.56% of the total shares.
The Vanguard Group, Inc. holds 1.73M shares, accounting for 3.60% of the total shares.
Private Advisory Group LLC holds 1.18M shares, accounting for 2.45% of the total shares.
Renaissance Technologies LLC holds 561.02K shares, accounting for 1.17% of the total shares.
Egan (Dwight H.) holds 748.18K shares, accounting for 1.55% of the total shares.
Orca Capital GmbH holds 2.19M shares, accounting for 4.56% of the total shares.
The Vanguard Group, Inc. holds 1.73M shares, accounting for 3.60% of the total shares.
Private Advisory Group LLC holds 1.18M shares, accounting for 2.45% of the total shares.
Renaissance Technologies LLC holds 561.02K shares, accounting for 1.17% of the total shares.
Egan (Dwight H.) holds 748.18K shares, accounting for 1.55% of the total shares.
What are the top three shareholder types of Co-Diagnostics Inc?
The top three shareholder types of Co-Diagnostics Inc are:
Ayrton Capital LLC
Orca Capital GmbH
The Vanguard Group, Inc.
Ayrton Capital LLC
Orca Capital GmbH
The Vanguard Group, Inc.
How many institutions hold shares of Co-Diagnostics Inc (CODX)?
As of 2025Q4, 80 institutions hold shares of Co-Diagnostics Inc, with a combined market value of approximately 11.14M, accounting for 13.43% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.57%.
What is the biggest source of revenue for Co-Diagnostics Inc?
In FY2025Q2, the -- business generated the highest revenue for Co-Diagnostics Inc, amounting to -- and accounting for --% of total revenue.
